Sutro Biopharma, Inc. - Common Stock (STRO)

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.

What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of March 10-14, 2025.

Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report.

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Sutro Biopharma reported $62 million in 2024 revenue, down from $153.7 million in 2023, and announced a pipeline restructuring.

Sutro Biopharma shares are trading lower by 4.3% during Tuesday's session. The company announced the pricing of an underwritten offering.

STRO stock results show that Sutro Biopharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

STRO stock results show that Sutro Biopharma missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.